(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 March 2003 (20.03.2003)

PCT

(10) International Publication Number
WO 03/022262 A1

(51) International Patent Classification[7]: A61K 31/205, 31/519, 31/4985, A61P 15/00, 15/10

(21) International Application Number: PCT/LV02/00004

(22) International Filing Date: 4 March 2002 (04.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P-01-00134 7 September 2001 (07.09.2001) LV

(71) Applicants and
(72) Inventors: **KALVINSH, Ivars** [LV/LV]; Libieshu 25, LV-5052 Ikshkile (LV). **VEVERIS, Maris** [LV/LV]; Vejavas 10/2, Apt. 20, LV- 1035 Riga (LV). **BIRMANS, Anatolijs** [LV/LV]; Hospitalu 8-35, LV- 1013 Riga (LV).

(74) Agent: **FOGEL, Abraham**; Alfa-Patents SIA, Viranes 2, LV- 1073 Riga (LV).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 03/022262 A1

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING GAMMA-BUTYROBETAINE

(57) Abstract: New medical use for gamma-butyrobetaine is disclosed. Also disclosed are pharmaceutical compositions, containing gamma-butyrobetaine or combination thereof with 3-(2,2,2-trimethylhydrazinium)propionate or sildenafil for oral, parenteral, subcutaneous, transdermal, topical, sublingual, intrauretral, intranasal or rectal application, useful for stimulation of sexual activity and potency in mammals. The disclosed compositions, when applied orally for 6 weeks to non-narcotized male rats substantially increase their sexual activity, decreasing the arousal time, increasing the number of copulations and resultativeness of mounting attempts. When applied by intracavernous or intravenous route said pharmaceutical compositions increase intracorporeal pressure and duration of erection, as well as restore stimulation-induced reflectory erection in narcotized animals.